Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omacetaxine, Cytarabine, and Decitabine in Older Patients With Newly Diagnosed AML
NCT02029417Phase 2Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jul 2014
- Primary completion
- Nov 2015
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of homoharringtonine in acute myeloid leukemia (AML), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Complete Response Rate at 4 years and Frequency of Adverse Events. Started Jul 2014; status: terminated.
02
Drugs
homoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02029417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02029417.